Since the improvement of chemotherapy and innovation of rituximab, about 60% of patients
with diffuse large B cell lymphoma (DLBCL) could receive long-term survival after firstline therapy.
Around 30% fail to respond or experience relapse considered as the relapsed/refractory DLBCL, the highdose
chemotherapy followed by autologous hematopoietic stem cell transplantation (auto-HSCT) has
been used as the second-line treatment. However, the patients relapse after auto-HSCT or not eligible for
the auto-HSCT have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is
the potentially curative way in such kind of patients. In this paper, we collected the published data about
patients with relapsed/refractory DLBCL who underwent allo-HSCT, demonstrated the appropriate candidate
for allo-HSCT, identified the effect of the donor types on the recipients, presented the major conditioning
regimens for allo-HSCT and figured out the outcomes of each conditioning regimen. We also tried
to identify the prognostic factors on the outcome which might shed some light on the further clinical application.